The size of the Metaxalone Market in the Asia Pacific is projected to hike at a healthy rate during the forecast period.
The rising number of musculoskeletal disorders among people, expanding medication research and development activities, a growing elderly population, and the increasing incidence of road accidents are a few of the factors encouraging the metaxalone market growth in the APAC region. One of the other factors driving the expansion of the Asia Pacific metaxalone market is the rise in the number of musculoskeletal disorders such as arthritis. Furthermore, incidents resulting in injuries, such as muscular or joint pain, are on the rise. Furthermore, with an increasing number of athlete gym institutions and a growing interest in fitness in urban life, the market for metaxalone is expected to rise rapidly during the forecast period.
Metaxalone is also used to treat elderly patients with joint, bone, and muscle disorders. Over the forecast period, the above aspects enable multiple potential prospects for the metaxalone market. Furthermore, the rise in the number of traffic accidents due to a lack of sufficient infrastructure has created several opportunities for metaxalone to expand as a muscle relaxant. Therefore, Metaxalone should only be taken with a doctor's prescription. Furthermore, with an increasing number of athlete gym institutions and a growing interest in fitness in urban life, the market for metaxalone is expected to rise rapidly during the forecast period.
Increased side effects such as vomiting, headache, nausea, and irritability, among others, are expected to hamper the expansion of the metaxalone market in the APAC region. Furthermore, the APAC metaxalone market is expected to face challenges due to strict regulatory approval. Furthermore, combining metaxalone with a central nervous system depressant can cause the patient to have major nervous system depression. Moreover, a lockdown limits the number of vehicles on the road due to the pandemic, reducing the number of accidents that impede the market's growth. Furthermore, the decline of several outside activities, such as sports and gymnasiums, has substantially impacted demand for metaxalone, which promotes muscle relaxation and has harmed the market's growth.
This research report on the APAC metaxalone market has been segmented and sub-segmented into the following categories.
By Indication:
By End User:
By Country:
Geographically, the growing popularity of athletics and gymnastics in Asia has resulted in a demand for metaxalone as a pain reliever for athletes. In addition, the World Health Organization and local government agencies have strengthened drug prescription guidelines, opening up substantial market prospects for metaxalone in the market. Metaxalone is a muscle relaxant used to relieve muscle tension and pain caused by sprains, strains, and other musculoskeletal problems. Metaxalone is a powerful muscle relaxant with minor adverse side effects. As a result of this quality, athletes in this region consider metaxalone the most outstanding alternative for muscle contraction protection. Furthermore, people may prefer hospitals due to the availability of qualified personnel, driving the industry’s growth in this region. This is primarily due to clinics that are open for more extended periods, boosting selling capacity and providing quick service. Both of these enhance demand for metaxalone and lead to market growth.
KEY MARKET PLAYERS:
Some of the key players dominating this market include Biosynth, Chunghwa Chemical Synthesis and Biotech, Sigma Aldrich, CDI Technology, Angelini, Pfizer, Aurum Pharmatech, Finetech Industry Limited, Biochem, and Oxchem Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Indication
5.1.1 Introduction
5.1.2 Bone Pain
5.1.3 Muscle Pain
5.1.4 Tunnel Syndrome
5.1.5 Joint Pain
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Indication
5.1.8 Market Attractiveness Analysis, By Indication
5.1.9 Market Share Analysis, By Indication
5.2 End User
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Clinics
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Indication
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Indication
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Indication
6.1.5.3 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Biosynth
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Chunghwa Chemical Synthesis and Biotech
8.3 Sigma Aldrich
8.4 CDI Technology
8.5 Angelini
8.6 Pfizer
8.7 Aurum Pharmatech
8.8 Finetech Industry Limited
8.9 Biochem
8.10 Oxchem Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
